Study Illustrates Adaptrin® Benefits with Atherosclerosis

STATEN ISLAND, N.Y.An Adaptrin® study has been published in the Journal of Cardiovascular Diseases and Diagnosis (JCDD), illustrating its atherosclerosis benefits.

The study, Tibetan Medicine: An Effective Botanical Supplement for Peripheral Vascular Circulation," authored by Dr. Vladimir Badmaev, MD, PhD, provides an instructive example of how a botanical and mineral formula Gabyr-Nirynga (camphor combination), referred as formula No. 28, has evolved into a contemporary application through scientific research (J Cardiovasc Dis Diagn 2013, 1:3 http://dx.doi.org/10.4172/jcdd.1000111).

 This developmental pathway has led to No. 28 (as Adaptrin®), a standardized nutraceutical with clinically proven efficacy in supporting against a form of atherosclerosisperipheral arterial disease (PAD).

The formulas mechanism of action has been described in Tibetan tradition based on its three groups of botanical and mineral ingredients: main active ingredients, auxiliary ingredients and components that offset the action of the first two groups and facilitate gastrointestinal absorption of the formula, according to the study.

Based on preclinical and clinical studies, several mechanisms of action relevant to alleviation of PAD have been discussed, such as an increase in threshold for platelet aggregation, lower total blood cholesterol and low-density lipoproteins (LDL), and prevention of blood lipid peroxidation.  A study in an animal model of CNS inflammation has shown that No. 28 can exert action as a biological response modifier improving response of the organism to chronic inflammation.

"This latter mechanism may be particularly relevant to the clinical benefits with No. 28 in patients with PAD, in view of cardiovascular disease increasingly considered as an outcome of a chronic inflammatory process," Dr. Badmaev said.